
Sameem Abedin
@sameem_abedin
Leukemia/BMT Doc, dad, steeler fan(atic)
ID: 1068639058207825920
30-11-2018 22:53:00
117 Tweet
131 Takipçi
85 Takip Edilen


CONGRESS | #ASH22 Sameem Abedin Sameem Abedin, Medical College of Wisconsin shows 53% 1 year OS and 32% at 2 years with salvage lintuzumab-Ac225 (actimab-A) plus CLAG-M in phase 1 trial in patients with R/R AML, with 64% progressing to allo-HSCT. #leusm #medicalcongress





In leukemias, are there any studies demonstrating benefit to post-HCT maintenance therapy in patients who enter transplant in an MRD negative state? Thanks Mehdi Hamadani, MD Shernan Holtan MD Chris Hourigan





